Ontex Group N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONXXF research report →
Price Chart
About the company
Ontex Group NV develops, produces, and sells baby, feminine, and adult care products in Belgium, the United Kingdom, Italy, the United States, France, Poland, and internationally. The company offers baby care products, such as baby diapers and pants, and wet wipes under the Moltex, Free Life, Baby Charm, Helen Harper, and Swimmies brands; and feminine care products, including sanitary towels, panty liners, and tampons under the ConfiDaily, SatinSense, All night protection, Libera Safe, 4-in-1 protection, Multi-liquid liner brand names. It also provides adult care products comprising adult pants and diapers, incontinence towels, and bed protection under the iD, SERENITY, lille, orizon, and Kylie, as well as Nefertiti brands.
- CEO
- Laurent Nielly
- IPO
- 2018
- Employees
- 7,765
- HQ
- Aalst, VLG, BE
Get TickerSpark's AI analysis on ONXXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $192.96M
- P/E
- -0.73
- Fwd P/E
- 5.85
- PEG
- 0.01
- P/S
- 0.08
- P/B
- 0.18
- EV/EBITDA
- 4.12
- Div Yield
- 0.00%
- Gross Margin
- 27.19%
- Op Margin
- 4.90%
- Net Margin
- -11.62%
- ROE
- -22.75%
- ROIC
- 5.78%
Latest fiscal year · YoY change
- Revenue
- $1.76B-5.3%
- Gross Profit
- $479.40M-11.8%
- Op Income
- $79.00M
- Net Income
- $-173,500,000-1784.5%
- EPS
- $-2.16-1761.5%
- OCF Growth
- -42.6%
- FCF Growth
- -58.6%
- 52W High
- $7.97
- 52W Low
- $2.35
- 50D MA
- $2.63
- 200D MA
- $4.32
- Beta
- 0.10
- RSI (14)
- 27
- Avg Volume
- 24
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ontex said 2025 was a disappointing year, with 5% like-for-like revenue decline, 10% adjusted EBITDA margin, negative free cash flow, and a 2026 plan for 10% EBITDA growth and leverage down to 3x or better.· February 12, 2026
- 2025 revenue fell 5% like-for-like, mainly from EUR 93 million of volume decline, with Baby Care softness the biggest drag.
- Adjusted EBITDA was EUR 184 million and margin was 10%, down 2 points year over year; Q4 margin fell to 9%.
- Free cash flow was minus EUR 25 million, while net debt ended at EUR 577 million and leverage rose to 3.3x after divestments and lower EBITDA.
- Management expects 2026 adjusted EBITDA to improve by 10%, with largely stable revenue, positive free cash flow after financing, and leverage at 3x or better.
- A strategic review has started to assess where to allocate capital and resources, with management emphasizing faster execution and value creation.
2025 revenue decreased 5% like-for-like, driven almost entirely by a EUR 93 million volume decline. Adjusted EBITDA was EUR 184 million, with a 10% margin, down 2 percentage points year over year. Adjusted profit from continuing operations was EUR 34 million versus EUR 76 million in 2024. Free cash flow was minus EUR 25 million, net debt was EUR 577 million versus EUR 612 million at end-2024, and leverage was 3.3x. In Q4, revenue was down 7.6% like-for-like and adjusted EBITDA margin was 9%, down 3 percentage points year over year. For 2026, management targets 10% adjusted EBITDA growth, largely stable revenue, positive free cash flow after financing, and leverage of 3x or better by year-end. CapEx is expected to return to 3.5% to 4.5% of revenue, and nonrecurring cash outflow is expected to be about EUR 20 million based on current plans.
Laurent Nielly struck a candid tone, calling 2025 disappointing and saying the company still needs to rebuild trust and improve its trajectory. He said the main issues were softer demand, slower execution in growing segments during the European transformation, supply disruption, and weaker contract manufacturing in North America. Strategically, he emphasized preserving competitive positions, resuming volume growth, improving productivity, and launching a broad strategic review to sharpen where Ontex can create value.
Geert Peeters focused on the mechanics behind the year’s decline and the balance sheet. He said the EUR 184 million of adjusted EBITDA was pressured by EUR 40 million of lower revenue impact, partially offset by EUR 69 million of net savings from the cost transformation program, while raw materials rose about 4% and other operating costs rose about 8%. He highlighted free cash flow before financing of plus EUR 18 million, but after EUR 43 million of financing cash outflow, free cash flow to equity holders was minus EUR 25 million. He also noted net debt fell to EUR 577 million, gross debt was EUR 647 million, liquidity was EUR 240 million, and debt maturity is extended to at least 2029.
Analysts focused on how 2026 will progress quarter by quarter, especially the weak Q1 setup, North American contract manufacturing, pricing versus raw materials, working capital, and cash outflows from restructuring. Management said Q1 2026 should be in line with Q4 2025, with improvements starting from Q2 and occurring quarter by quarter, and that U.S. contract manufacturing sales will be lower year over year while retail brand growth continues. On working capital, Geert said receivables factoring at year-end was EUR 185 million and that there is no unusual issue expected in 2026, while on restructuring he guided to about EUR 20 million of cash outflow based on current plans. On Russia, Laurent said the business is still about 5% of revenues and will be considered within the broad strategic review, but no conclusion is being pre-judged.
Management sees 2026 as a year of gradual improvement, with 10% adjusted EBITDA growth, stable revenue, and positive free cash flow after financing. They pointed to ongoing cost savings, better operational stability, new and ramped-up contracts, and capacity additions in Adult Care as supports for the rebound. The strategic review could also uncover additional value creation opportunities.
The company still faces weak consumer demand, especially in Baby Care, and North American contract manufacturing will remain a year-over-year drag in early 2026. Management also acknowledged that Q1 2026 will be soft, potentially in line with Q4 2025, while leverage remains elevated at 3.3x and free cash flow was negative in 2025. The strategic review signals that the current setup may still need more structural change before results improve materially.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 73.9%
- Shares Outstanding
- 79.73M
- Float Shares
- 58.92M
Our ONXXF coverage
Recent articles, reports, and earnings notes.
No research on ONXXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ONXXF report →Ontex Group NV (ONXYY) Q1 2026 Earnings Call Transcript
seekingalpha.com · Apr 29
Ontex Group NV (ONXXF) Q2 2025 Earnings Call Transcript
seekingalpha.com · Aug 1
Ontex Group NV (ONXXF) Q1 2025 Earnings Call Transcript
seekingalpha.com · Apr 30
Ontex Group NV (ONXXF) Q4 2024 Earnings Call Transcript
seekingalpha.com · Feb 19
Ontex Group NV (ONXXF) Q3 2024 Earnings Call Transcript
seekingalpha.com · Oct 24
Ontex Group NV (ONXXF) Q2 2024 Earnings Call Transcript
seekingalpha.com · Aug 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.